Brainstorm presents new biomarker analyses from nurown's phase 3 als trial at the als one research symposium

Nurown® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced als and less advanced disease, confirming the importance of accounting for alsfrs-r floor effects when evaluating clinical endpoints new york , oct. 7, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of nurown® in amyotrophic lateral sclerosis (als) at the ongoing 5th annual als one research symposium. the presentation was delivered by dr. stacy lindborg, chief development officer at brainstorm, and entitled, "the relationship between csf biomarkers and efficacy of treatment with nurown (msc-ntf cells).
BCLI Ratings Summary
BCLI Quant Ranking